Health Care & Life Sciences » Biotechnology | Palatin Technologies Inc.

Palatin Technologies Inc. | Mutual Funds

Mutual Funds that own Palatin Technologies Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
5,422,870
2.69%
0
0%
07/31/2018
iShares Russell 2000 ETF
4,105,661
2.04%
-2,193
0.01%
09/06/2018
Vanguard Extended Market Index Fund
2,204,905
1.09%
0
0%
07/31/2018
iShares Russell 2000 Growth ETF
1,815,041
0.9%
0
0.02%
09/06/2018
Fidelity Spartan Extended Market Index Fund
722,863
0.36%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
546,000
0.27%
546,000
0.13%
12/31/2017
iShares Micro Cap ETF
537,983
0.27%
0
0.05%
09/06/2018
Schwab Small Cap Index Fund
365,200
0.18%
365,200
0.01%
06/30/2018
347,368
0.17%
0
0.02%
07/31/2018
Fidelity Spartan Total Market Index Fund
331,257
0.16%
0
0%
07/31/2018

About Palatin Technologies

View Profile
Address
Cedar Brook Corporate Center
Cranbury New Jersey 08512
United States
Employees -
Website http://www.palatin.com
Updated 07/08/2019
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.